HTRA1 levels are downregulated in pancreatic, gastric, prostate, lung, bladder, hepatocellular carcinoma, ovarian, and breast cancers and correlate with increased tumor growth, epithelial-mesenchymal transition (EMT), metastasis, and chemoresistance [29,30]. Here, HTRA1 is linked to breast carcinoma.